Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

HOTH earnings analysis

Filed May 15, 2026 · Our reading of the company's report

The latest report

Hoth Therapeutics, Inc. exhibited a significant reduction in its net loss for Q1 2026 compared to Q1 2025, decreasing from a loss of $3,476,000 (-$0.27 EPS) to $2,692,000 (-$0.17 EPS). Despite maintaining the same…

Read full summary

Hoth Therapeutics, Inc. exhibited a significant reduction in its net loss for Q1 2026 compared to Q1 2025, decreasing from a loss of $3,476,000 (-$0.27 EPS) to $2,692,000 (-$0.17 EPS). Despite maintaining the same segment focus, the company has not yet generated revenue and continues to rely on equity and debt financing for operations. With a cash position of approximately $4,047,000, HOTH faces liquidity challenges going forward without additional funding.

Read the original on SEC.gov

Reported figures

Earnings per share
$-0.17

What stood out

  • Reduced Net Loss

    Net loss narrowed to $2,692,000 in Q1 2026 from $3,476,000 in Q1 2025, reflecting a tighter expense management.

  • Decreased G&A Expenses

    General and administrative expenses dropped 25.6%, from $1,517,000 in Q1 2025 to $1,129,000 in Q1 2026.

  • Increased R&D Efficiency

    R&D costs decreased to $1,519,000 in Q1 2026 from $1,959,000 in Q1 2025 as the company streamlined its focus on key projects.

  • Cash Position Improvement

    As of March 31, 2026, cash and cash equivalents stood at $4,047,000, ensuring operational liquidity.

  • Warrants Issued

    Net proceeds of approximately $2,000,000 were raised from the sale of 2,857,144 shares of common stock at $0.70.

  • Stable Working Capital

    Working capital is approximately $3,425,000, with the ability to support operations through the current quarter.

What to watch

  • Ongoing Losses

    The company reported net losses of $2,692,000 in Q1 2026, reflecting challenges in achieving operational profitability.

  • Liquidity Concerns

    Firm projects a risk of failing to fund operations for at least 12 months without additional financing due to current cash availability.

  • Dependence on Financing

    Significant future funding will be necessary for continued clinical and pre-clinical activities without any current revenue generation.

Management's outlook

Management did not provide explicit numeric guidance but indicated challenges in securing funding.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.